195 related articles for article (PubMed ID: 27783363)
1. Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.
Tout M; Gagez AL; Leprêtre S; Gouilleux-Gruart V; Azzopardi N; Delmer A; Mercier M; Ysebaert L; Laribi K; Gonzalez H; Paintaud G; Cartron G; Ternant D
Clin Pharmacokinet; 2017 Jun; 56(6):635-647. PubMed ID: 27783363
[TBL] [Abstract][Full Text] [Related]
2. The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition.
Bensalem A; Cartron G; Specks U; Mulleman D; Gyan E; Cornec D; Desvignes C; Casasnovas O; Lamy T; Leprêtre S; Paintaud G; Ternant D
Clin Pharmacokinet; 2022 Mar; 61(3):423-437. PubMed ID: 34773607
[TBL] [Abstract][Full Text] [Related]
3. Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients.
Lioger B; Edupuganti SR; Mulleman D; Passot C; Desvignes C; Bejan-Angoulvant T; Thibault G; Gouilleux-Gruart V; Mélet J; Paintaud G; Ternant D
Br J Clin Pharmacol; 2017 Aug; 83(8):1773-1781. PubMed ID: 28230269
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
Cartron G; Dacheux L; Salles G; Solal-Celigny P; Bardos P; Colombat P; Watier H
Blood; 2002 Feb; 99(3):754-8. PubMed ID: 11806974
[TBL] [Abstract][Full Text] [Related]
5. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
[TBL] [Abstract][Full Text] [Related]
6. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.
Bagacean C; Tempescul A; Ternant D; Banet A; Douet-Guilbert N; Bordron A; Bendaoud B; Saad H; Zdrenghea M; Berthou C; Paintaud G; Renaudineau Y
J Immunother Cancer; 2019 Jan; 7(1):22. PubMed ID: 30696487
[TBL] [Abstract][Full Text] [Related]
7. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
Beum PV; Peek EM; Lindorfer MA; Beurskens FJ; Engelberts PJ; Parren PW; van de Winkel JG; Taylor RP
J Immunol; 2011 Sep; 187(6):3438-47. PubMed ID: 21841127
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.
Marquez ME; Hernández-Uzcátegui O; Cornejo A; Vargas P; Da Costa O
Br J Haematol; 2015 Apr; 169(2):211-8. PubMed ID: 25612644
[TBL] [Abstract][Full Text] [Related]
10. Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: A pilot study.
Ternant D; Monjanel H; Venel Y; Prunier-Aesch C; Arbion F; Colombat P; Paintaud G; Gyan E
Br J Clin Pharmacol; 2019 Sep; 85(9):2002-2010. PubMed ID: 31112622
[TBL] [Abstract][Full Text] [Related]
11. Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups.
Gagez AL; Tuaillon E; Cezar R; Dartigeas C; Mahé B; Letestu R; Maisonneuve H; Gouilleux-Gruart V; Bollore K; Ferrant E; Aurran T; Feugier P; Leprêtre S; Cartron G
Blood Cancer J; 2016 Jan; 6(1):e389. PubMed ID: 26800078
[No Abstract] [Full Text] [Related]
12. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.
Struemper H; Sale M; Patel BR; Østergaard M; Österborg A; Wierda WG; Hagenbeek A; Coiffier B; Jewell RC
J Clin Pharmacol; 2014 Jul; 54(7):818-27. PubMed ID: 24443277
[TBL] [Abstract][Full Text] [Related]
13. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
Mankaï A; Buhé V; Hammadi M; Youinou P; Ghedira I; Berthou C; Bordron A
Ann N Y Acad Sci; 2009 Sep; 1173():721-8. PubMed ID: 19758221
[TBL] [Abstract][Full Text] [Related]
14. Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.
Pickartz T; Ringel F; Wedde M; Renz H; Klein A; von Neuhoff N; Dreger P; Kreuzer KA; Schmidt CA; Srock S; Schoeler D; Schriever F
Exp Hematol; 2001 Dec; 29(12):1410-6. PubMed ID: 11750099
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.
Robinson JI; Md Yusof MY; Davies V; Wild D; Morgan M; Taylor JC; El-Sherbiny Y; Morris DL; Liu L; Rawstron AC; Buch MH; Plant D; Cordell HJ; Isaacs JD; Bruce IN; Emery P; Barton A; Vyse TJ; Barrett JH; Vital EM; Morgan AW; ;
EBioMedicine; 2022 Dec; 86():104343. PubMed ID: 36371989
[TBL] [Abstract][Full Text] [Related]
16. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.
Lim SH; Vaughan AT; Ashton-Key M; Williams EL; Dixon SV; Chan HT; Beers SA; French RR; Cox KL; Davies AJ; Potter KN; Mockridge CI; Oscier DG; Johnson PW; Cragg MS; Glennie MJ
Blood; 2011 Sep; 118(9):2530-40. PubMed ID: 21768293
[TBL] [Abstract][Full Text] [Related]
17. Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells.
Mankaï A; Bordron A; Renaudineau Y; Martins-Carvalho C; Takahashi S; Ghedira I; Berthou C; Youinou P
Cancer Res; 2008 Sep; 68(18):7512-9. PubMed ID: 18794139
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
[TBL] [Abstract][Full Text] [Related]
19. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.
Pavlasova G; Borsky M; Svobodova V; Oppelt J; Cerna K; Novotna J; Seda V; Fojtova M; Fajkus J; Brychtova Y; Doubek M; Pospisilova S; Mayer J; Mraz M
Leukemia; 2018 Sep; 32(9):2028-2031. PubMed ID: 30030508
[No Abstract] [Full Text] [Related]
20. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.
Klepfish A; Gilles L; Ioannis K; Rachmilewitz EA; Schattner A
Ann N Y Acad Sci; 2009 Sep; 1173():865-73. PubMed ID: 19758239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
